Baird analyst Jon Vruwink assumes Roper Techs (NYSE:ROP) with a Neutral rating and announces Price Target of $476.
INVO Bioscience Enters 1-Year Distribution Agreement For Taiwan
INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device
